1991
DOI: 10.1111/j.1348-0421.1991.tb01552.x
|View full text |Cite
|
Sign up to set email alerts
|

Macrophage Migration Inhibitory Factor (MIF) Produced by a Human T Cell Hybridoma Clone

Abstract: A human T cell hybridoma clone, F5, producing high levels of macrophage migration inhibitory factor (MIF) was established by the emetine-actinomycin D selection method. This clone produced two species of MIF which were separated on a Phenyl Sepharose column. We purified MIF-2 (the more hydrophobic species of the two) to homogeneity from the conditioned medium of stimulated F5 cells by a series of steps that included hydrophobic chromatography, ion-exchange chromatography. Ricinus communis lectin affinity chrom… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

1992
1992
2016
2016

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 17 publications
(10 reference statements)
0
2
0
Order By: Relevance
“…It is now known to be widely expressed in various cell types, including activated T cells, macrophages and anterior pituitary gland cells, etc. [ 7 10 ]. In addition to macrophage migration inhibition, other functions of MIF have yet to be fully elucidated.…”
Section: Discussionmentioning
confidence: 99%
“…It is now known to be widely expressed in various cell types, including activated T cells, macrophages and anterior pituitary gland cells, etc. [ 7 10 ]. In addition to macrophage migration inhibition, other functions of MIF have yet to be fully elucidated.…”
Section: Discussionmentioning
confidence: 99%
“…(21)(22)(23)(24)(25)(26)(27)(28)(29)(30) This cell selection method was used to omit HAT cytotoxicity. The F3B6 heteromyeloma cells were cultured at 10 6 streptomycin, 0.1 mM hypoxanthine, 0.016 mM thymidine (all from Sigma, St. Louis, MO), and 10% fetal bovine serum (FBS, Gibco, BRL Life Technologies) (complete RPMI medium) in the presence of 5Â10 À5 M emetine-Cl and 0.25 mg=mL actinomycin D (both from Sigma) for 2 h in a humidified 378C, 5% CO 2 incubator prior to fusion.…”
Section: Pretreatment Of F3b6 Cells With Actinomycin D and Emetinementioning
confidence: 99%